Prevalence of Factor V 1691 G–A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Eroğlu, Aydan; Ulu, Arzu; Çam, Ragıp; Kurtman, Cengiz; Akar, Nejat

doi:10.1007/s11239-006-9001-z

Cited by 31 publications

(17 citation statements)

References 22 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTM and MTHFR mutations were not found as VTE risk factors in this population. The same results were observed in a Turkish population [8] , yet in the large Dutch study by Blom et al [7] , FVL and PTM were associated with increased VTE risk in cancer patients. The average age of cancer patients is around 60 years, and elderly patients are known to have high rates of VTE compared to the general young population even without inherited thrombophilic risk factors.…”

Section: Summary and Future Directionssupporting

confidence: 76%

See 1 more Smart Citation

Thrombophilia and Cancer

Horowitz

Brenner²

2007

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Inherited and acquired thrombophilia are well-known risk factors for venous thromboembolism. The incidence of thrombotic events in cancer patients is increased compared to normal population. Data on inherited thrombophilia and cancer is limited. Most studies are small, and results are varied by geography, tumor type, stage of disease and therapy. Nevertheless, it seems that factor V Leiden and prothrombin mutation may increase VTE risk in cancer patients. Data also exist for hyperhomocysteinemia. Cancer patients with thrombophilia who have a central vein catheter are a special group with increased venous thrombotic event (VTE) risk. Among acquired risk factors, antiphospholipid antibodies are common in cancer patients, especially in lymphoproliferative diseases. Published data suggests that the risk of thrombotic events, venous and arterial, is increased in cancer patients with antiphospholipid antibodies. The questions of screening cancer patients for inherited thrombophilia or antiphospholipid antibodies are unclear. There is no data on primary VTE prophylaxis in cancer patients with thrombophilia and prophylaxis for cancer patients with central vein catheters is controversial.

show abstract

Section: Summary and Future Directionssupporting

confidence: 76%

“…In a recent study from Turkey the prevalence of FVL was 30.2% in cancer patients with VTE compared to cancer patients without VTE (3.7%, p ! 0.001) [8] . There was no significant difference in the prevalence of PTM among the groups (p 1 0.05).…”

Section: Introductionmentioning

confidence: 99%

Thrombophilia and Cancer

Horowitz

Brenner²

2007

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…FVL, prothrombin mutation) in cancer patients have shown inconsistent and conflicting results, likely because of insufficient statistical power due to small populations of patients. [24][25][26][27] As a consequence, knowledge on the biological interaction between cancer and inherited risk factors for VTE is limited. The aim of the present study was to investigate the joint effect of inherited risk variants of F5, FVL and rs4524, and active cancer on the absolute and relative risks of VTE in a population-based case-cohort study.…”

Section: Introductionmentioning

confidence: 99%

Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism

et al. 2016

View full text Add to dashboard Cite

“…Conversely, Eroglu et al [18] observed that FII G20210A polymorphism was not related to increased risk of VTE. In one prospective study, the prevalence and clinical significance of four gene variations (FVL, FII G20210A, FXIII MTHFR C677T and Val34Leu) were evaluated in cancer patients, with and without VTE.…”

Section: Discussionmentioning

confidence: 99%

Is Genetic Screening Necessary for Determining the Possibility of Venous Thromboembolism in Cancer Patients?

Onur

Kurdal²,

Tuğrul

et al. 2011

Med Princ Pract

View full text Add to dashboard Cite

Objective: To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, β-ﬁbrinogen -455 G → A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients. Subjects and Methods: Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups. Results: Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk. Conclusion: There is no possible benefit from genetic screening tests regarding VTE in cancer patients.

show abstract

Prevalence of Factor V 1691 G–A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Abstract: The study suggested that cancer patients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.

Cited by 31 publications

References 22 publications

Thrombophilia and Cancer

Thrombophilia and Cancer

Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism

Is Genetic Screening Necessary for Determining the Possibility of Venous Thromboembolism in Cancer Patients?

Contact Info

Product

Resources

About